
Full profile: /officials/M001237
Source: Congress.gov · FEC
Members who have signed on to support this bill since introduction. Source: Congress.gov.
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-03-27
Source: Congress.gov
Currently in
Previously
This bill would require pharmaceutical companies to disclose more information about how they set drug prices and would give the government more power to negotiate lower prices for medications, particularly for Medicare patients. The changes would likely affect both drug manufacturers and patients who struggle to afford prescription medications. The bill has been referred to multiple House committees for review and consideration.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Bills by the same sponsor or covering overlapping subjects.